The Real Talk: Should You Do It
Overlooked at First, GLP-1 Receptor Agonists Suddenly Took Bariatric Medicine by Storm Initially, the pharmaceutical industry didnt pay a lot of attention to the drug category
More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ Cancer Information for Health Professionals pages
G., Furuya, W., Brumell, J
Pregnancy and lactation safety has not been systematically studied, and as with most cosmetic and research compounds lacking definitive pregnancy safety data, conservative practice typically suggests avoiding use during pregnancy unless clearly needed, though the natural occurrence of GHK-Cu in the body and minimal systemic absorption from topical use suggest risk is likely to be low
Jenn and I discuss: How natural GLP-1 production can decline with age Why under-fueling is still the primary issue for many athletes Different types and forms of GLP-1 meds Who should (and shouldn't) consider these medications Potential risks of GLP-1 use, including muscle loss, bone density loss, and GI distress Potential benefits to inflammation, autoimmune conditions, gut health, and mood Nutrition and supplement strategies when appetite is lower Dosing and microdosing for therapeutic use, not just weight loss Why some athletes cycle on and off these meds, or may only need them for a short period of time Why Jenn takes most clients off GLP-1s during race training The stigma around GLP-1 use among athletes Jenn's own story: early menopause, a cardiovascular family history, and how a short course changed her running Why solid diet and lifestyle habits must always come first I hope this episode helps you better understand the complexities of GLP-1 medications in endurance athletes, and why there's rarely a simple yes-or-no answer to the questions we explore together
